Loading...
Docoh
Log in Free sign up

Orphazyme A/S (ORPHY)

Company profile

Ticker
ORPHY, ORPHY
Exchange
NASDAQ
Website
www.orphazyme.com/
CEO
Kim Stratton
Employees
Incorporated
Denmark
Location
Denmark
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie ...
SEC CIK
0001764791
Corporate docs

ORPHY stock data

News

From Benzinga Pro
KemPharm Acquires Battered Orphazyme's Arimoclomol Program For $13M
16 May 22
Orphazyme Announced Notice Received from the Depositary to Holders of ADSs Regarding Termination of Deposit Agreement
6 Apr 22
Orphazyme A/S in restructuring (ORPHA.CO) ("Orphazyme" or the "Company"), a late-stage biopharmaceutical company, has today received a notice from The Bank of New York Mellon, as depositary (the "Depositary"), that a notification has been sent to holders of American Depositary Shares ("ADSs") evidenced by American Depositary Receipts ("ADRs") representing deposited common shares of the Company, re

Calendar

2 Mar 21
26 Jun 22
31 Dec 22

Financial summary

Financial statements Chart ORPHY financial data
Quarter (USD) Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Financial data from company earnings reports.

Institutional ownership, Q4 2021

ORPHY institutional ownership history Ownership history
21.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 26 26 –
Opened positions 4 8 -50.0%
Closed positions 4 7 -42.9%
Increased positions 7 6 +16.7%
Reduced positions 9 4 +125.0%
13F shares Current Prev Q Change
Total value 47.64M 71.57M -33.4%
Total shares 7.47M 7.27M +2.7%
Total puts 144.4K 228.1K -36.7%
Total calls 325.2K 159.2K +104.3%
Total put/call ratio 0.4 1.4 -69.0%
Largest owners Shares Value Change
LSP V Cooperatieve U.A. 2.6M $6.26M -4.2%
Sunstone Life Science Ventures Fund Ii K/S 1.79M $19.21M 0.0%
Cooperatieve AESCAP Venture I U.A. 1.76M $18.86M 0.0%
Renaissance Technologies 271.99K $656K +150.0%
Geode Capital Management 177.07K $426K +590.6%
Two Sigma Investments 141.12K $340K -41.2%
Profund Advisors 127.52K $307K NEW
Susquehanna International 114.37K $276K -26.5%
Optiver Holding B.V. 106.84K $358K +81.8%
Citadel Advisors 95.01K $229K NEW
Largest transactions Shares Bought/sold Change
Renaissance Technologies 271.99K +163.19K +150.0%
Geode Capital Management 177.07K +151.43K +590.6%
Profund Advisors 127.52K +127.52K NEW
LSP V Cooperatieve U.A. 2.6M -114.67K -4.2%
Two Sigma Investments 141.12K -98.82K -41.2%
Citadel Advisors 95.01K +95.01K NEW
Blueshift Asset Management 0 -82.34K EXIT
UBS UBS Group AG - Registered Shares 70K +67.24K +2431.6%
Simplex Trading 4.62K -64.16K -93.3%
Optiver Holding B.V. 106.84K +48.08K +81.8%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Biogen • Cyclo Therapeutics • Cytokinetics • Sanofi • Mitsubishi Tanabe Pharma • MAA • E-scape Bio • IntraBio

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
From filing 20-F 2020 FY
Financial reports
20-F
2020 FY
Annual report (foreign)
2 Mar 21
Current reports
View all
6-K
Updated notice to holders of ADSs regarding termination of Deposit Agreement
21 Jun 22
6-K
Current report (foreign)
8 Jun 22
6-K
Current report (foreign)
31 May 22
6-K
Current report (foreign)
23 May 22
6-K
Current report (foreign)
18 May 22
6-K
Updated Financial Calendar for 2022
16 May 22
6-K
Current report (foreign)
16 May 22
6-K
Orphazyme announces update on in-court restructuring proceedings
29 Apr 22
6-K
Current report (foreign)
29 Apr 22
6-K
Current report (foreign)
7 Apr 22
Registration and prospectus
View all
15-12B
Securities registration termination
31 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 22
POS AM
Prospectus update (post-effective amendment)
21 Mar 22
25
Voluntary exchange delisting
21 Mar 22
424B5
Prospectus supplement for primary offering
4 Nov 21
F-3
Shelf registration (foreign)
15 Oct 21
S-8
Registration of securities for employees
29 Apr 21
S-8
Registration of securities for employees
9 Oct 20
424B4
Prospectus supplement with pricing info
29 Sep 20
Proxies
No filings
Other
View all
EFFECT
Notice of effectiveness
24 Mar 22
EFFECT
Notice of effectiveness
25 Oct 21
CORRESP
Correspondence with SEC
19 Oct 21
UPLOAD
Letter from SEC
19 Oct 21
EFFECT
Notice of effectiveness
29 Sep 20
CORRESP
Correspondence with SEC
27 Sep 20
UPLOAD
Letter from SEC
27 Sep 20
CORRESP
Correspondence with SEC
24 Sep 20
CORRESP
Correspondence with SEC
24 Sep 20
CERT
Certification of approval for exchange listing
24 Sep 20
Ownership
SC 13G/A
Orphazyme A/S / LSP V Cooperatieve U.A. ownership change
3 Feb 22
SC 13G
Orphazyme A/S / SUNSTONE LIFE SCIENCE VENTURES FUND II K/S ownership change
11 Feb 21
SC 13G
Orphazyme A/S / Cooperatieve AESCAP Venture I U.A. ownership change
9 Feb 21
SC 13G
Orphazyme A/S / LSP V Cooperatieve U.A. ownership change
8 Feb 21

Transcripts

2021 Q2
Earnings call transcript
31 Aug 21

Reddit threads

View all